The history of ALK is a history of ‘firsts’. Decades of pushing boundaries and raising standards have placed us at the forefront of our industry and for more than 100 years, we have consistently devised and developed major advances for the treatment of allergy.
Ever since 1923, when pharmacist Peter Barfod and physician Kaj Baagøe documented the first pharmaceutically manufactured allergy preparation, ALK has led the way in allergy treatment, and our history includes demonstrating how to manufacture allergen extracts, establishing a standardised method for large-scale manufacturing, and introducing new, more convenient treatment formulations.
In 2005, ALK became a listed company. Although traded on the NASDAQ Copenhagen (OMX: ALK B), ALK has an unusually stable ownership, with two shareholders having notified shareholdings of 5% or more. By supporting independent research at the highest level, our owners strive to significantly improve people’s health and well-being.
The Lundbeck Foundation, one of Denmark’s largest enterprise foundations, is the controlling shareholder of ALK, holding 67% of the votes and 40% of the capital.
